These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 31361031)

  • 1. The role of adenosine receptors in mood and anxiety disorders.
    van Calker D; Biber K; Domschke K; Serchov T
    J Neurochem; 2019 Oct; 151(1):11-27. PubMed ID: 31361031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of glial adenosine receptors in neural resilience and the neurobiology of mood disorders.
    van Calker D; Biber K
    Neurochem Res; 2005 Oct; 30(10):1205-17. PubMed ID: 16341582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How does adenosine control neuronal dysfunction and neurodegeneration?
    Cunha RA
    J Neurochem; 2016 Dec; 139(6):1019-1055. PubMed ID: 27365148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of purinergic signaling in depressive disorders.
    Sperlagh B; Csolle C; Ando RD; Goloncser F; Kittel A; Baranyi M
    Neuropsychopharmacol Hung; 2012 Dec; 14(4):231-8. PubMed ID: 23269209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Purinergic signalling in brain ischemia.
    Pedata F; Dettori I; Coppi E; Melani A; Fusco I; Corradetti R; Pugliese AM
    Neuropharmacology; 2016 May; 104():105-30. PubMed ID: 26581499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Creatine, similarly to ketamine, affords antidepressant-like effects in the tail suspension test via adenosine A₁ and A2A receptor activation.
    Cunha MP; Pazini FL; Rosa JM; Ramos-Hryb AB; Oliveira Á; Kaster MP; Rodrigues AL
    Purinergic Signal; 2015 Jun; 11(2):215-27. PubMed ID: 25702084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain adenosine receptors as targets for therapeutic intervention in neurodegenerative diseases.
    Abbracchio MP; Cattabeni F
    Ann N Y Acad Sci; 1999; 890():79-92. PubMed ID: 10668415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galanin receptor antagonists : a potential novel pharmacological treatment for mood disorders.
    Ogren SO; Kuteeva E; Hökfelt T; Kehr J
    CNS Drugs; 2006; 20(8):633-54. PubMed ID: 16863269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Caffeine Reverts Memory But Not Mood Impairment in a Depression-Prone Mouse Strain with Up-Regulated Adenosine A
    Machado NJ; Simões AP; Silva HB; Ardais AP; Kaster MP; Garção P; Rodrigues DI; Pochmann D; Santos AI; Araújo IM; Porciúncula LO; Tomé ÂR; Köfalvi A; Vaugeois JM; Agostinho P; El Yacoubi M; Cunha RA; Gomes CA
    Mol Neurobiol; 2017 Mar; 54(2):1552-1563. PubMed ID: 26860412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Pattern to Link Adenosine Signaling, Circadian System, and Potential Final Common Pathway in the Pathogenesis of Major Depressive Disorder.
    Wang XL; Gardner W; Yu SY; Serchov T
    Mol Neurobiol; 2022 Nov; 59(11):6713-6723. PubMed ID: 35999325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GABA release modified by adenosine receptors in mouse hippocampal slices under normal and ischemic conditions.
    Saransaari P; Oja SS
    Neurochem Res; 2005 Apr; 30(4):467-73. PubMed ID: 16076017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of chronic administration of adenosine antagonists on adenosine A1 and A2a receptors in mouse brain.
    Traversa U; Rosati AM; Florio C; Vertua R
    In Vivo; 1994; 8(6):1073-8. PubMed ID: 7772740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenosine Receptors in Neuropsychiatric Disorders: Fine Regulators of Neurotransmission and Potential Therapeutic Targets.
    Pasquini S; Contri C; Merighi S; Gessi S; Borea PA; Varani K; Vincenzi F
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guanosine Anxiolytic-Like Effect Involves Adenosinergic and Glutamatergic Neurotransmitter Systems.
    Almeida RF; Comasseto DD; Ramos DB; Hansel G; Zimmer ER; Loureiro SO; Ganzella M; Souza DO
    Mol Neurobiol; 2017 Jan; 54(1):423-436. PubMed ID: 26742520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melatonin MT
    Comai S; Lopez-Canul M; De Gregorio D; Posner A; Ettaoussi M; Guarnieri FC; Gobbi G
    Pharmacol Res; 2019 Jun; 144():343-356. PubMed ID: 31029764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonism of adenosine receptors by caffeine and caffeine metabolites in equine forebrain tissues.
    Chou CC; Vickroy TW
    Am J Vet Res; 2003 Feb; 64(2):216-24. PubMed ID: 12602592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guanosine Attenuates Behavioral Deficits After Traumatic Brain Injury by Modulation of Adenosinergic Receptors.
    Dobrachinski F; Gerbatin RR; Sartori G; Golombieski RM; Antoniazzi A; Nogueira CW; Royes LF; Fighera MR; Porciúncula LO; Cunha RA; Soares FAA
    Mol Neurobiol; 2019 May; 56(5):3145-3158. PubMed ID: 30105669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of adenosine A1 and A2A receptors modulates dopamine D2 receptor-induced responses in stably transfected human neuroblastoma cells.
    Salim H; Ferré S; Dalal A; Peterfreund RA; Fuxe K; Vincent JD; Lledo PM
    J Neurochem; 2000 Jan; 74(1):432-9. PubMed ID: 10617149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenosine receptors and Huntington's disease.
    Lee CF; Chern Y
    Int Rev Neurobiol; 2014; 119():195-232. PubMed ID: 25175968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Caffeine acts through neuronal adenosine A2A receptors to prevent mood and memory dysfunction triggered by chronic stress.
    Kaster MP; Machado NJ; Silva HB; Nunes A; Ardais AP; Santana M; Baqi Y; Müller CE; Rodrigues AL; Porciúncula LO; Chen JF; Tomé ÂR; Agostinho P; Canas PM; Cunha RA
    Proc Natl Acad Sci U S A; 2015 Jun; 112(25):7833-8. PubMed ID: 26056314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.